Rituxan in Churg Strauss Syndrome With Renal Involvement
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of
eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS
patients develop kidney disease. The goal of this pilot study was to evaluate the safety and
effectiveness of Rituximab in inducing remission of kidney disease in patients with CSS.
Phase:
Phase 2
Details
Lead Sponsor:
Fernando Fervenza
Collaborators:
Biogen Genentech, Inc. National Center for Research Resources (NCRR)